Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

NCT00765817 on ClinicalTrials.gov · last registry update 2016-10-24

Finished January 2010, after enrolling 261 people. Primary outcome, as filed: Change in Glycosylated Hemoglobin (HbA1c). exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: AstraZeneca
Sponsor type: Industry
Enrollment: 261
Started: 2008-10
Primary completion: 2010-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Glycosylated Hemoglobin (HbA1c)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.